Comment
doi: 10.1016/S1470-2045(07)70152-3.
MRC RT01: an important trial
- PMID: 17540300
- DOI: 10.1016/S1470-2045(07)70152-3
Item in Clipboard
Comment
MRC RT01: an important trial
Lancet Oncol.
2007 Jun.
No abstract available
Comment on
-
Escalated-dose versus standard-dose conformal radiotherapy in prostate cancer: first results from the MRC RT01 randomised controlled trial.Lancet Oncol. 2007 Jun;8(6):475-87. doi: 10.1016/S1470-2045(07)70143-2. Lancet Oncol. 2007. PMID: 17482880 Clinical Trial.
Similar articles
-
[Cancer of the prostate: importance of androgen deprivation and radiotherapy].Rev Med Suisse. 2005 May 11;1(19):1303-6. Rev Med Suisse. 2005. PMID: 15962630 Review. French. No abstract available.
-
Apples and oranges. Re: 7.4-year update of the ongoing bicalutamide Early Prostate Cancer (EPC) trial programme.BJU Int. 2006 Mar;97(3):435-8. doi: 10.1111/j.1464-410X.2006.06088.x. BJU Int. 2006. PMID: 16469001 No abstract available.
-
Toward the optimal use of androgen suppression therapy in the radiotherapeutic management of prostate cancer.J Clin Oncol. 2007 Jan 1;25(1):8-9. doi: 10.1200/JCO.2006.08.8260. J Clin Oncol. 2007. PMID: 17194901 No abstract available.
-
Risk-based management of prostate cancer.N Engl J Med. 2011 Jul 14;365(2):169-71. doi: 10.1056/NEJMe1103829. N Engl J Med. 2011. PMID: 21751910 No abstract available.
-
Short-term androgen deprivation therapy for patients with intermediate-risk prostate cancer undergoing dose-escalated radiotherapy: the standard of care?Lancet Oncol. 2012 Jun;13(6):e259-69. doi: 10.1016/S1470-2045(12)70084-0. Lancet Oncol. 2012. PMID: 22652234 Review.
Cited by
-
Dose-escalated radiotherapy for clinically localized and locally advanced prostate cancer.Cochrane Database Syst Rev. 2023 Mar 8;3(3):CD012817. doi: 10.1002/14651858.CD012817.pub2. Cochrane Database Syst Rev. 2023. PMID: 36884035 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
